Key Information
Source
The New England Journal of Medicine
Year
2021
summary/abstract
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression.
Abstract Source
https://www.nejm.org/doi/full/10.1056/NEJMoa2028631
DOI
10.1056/NEJMoa2028631
Organisation
University of Athens, School of Medicine, Athens; The Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and the Department of Molecular Medicine, University of Pavia, Italy (G.P., G.M.); University Utrecht, Netherlands; University of Groningen, Netherlands; University College London, UK; Centre Hospitalier Universitaire, France; University of Texas, USA